Fol. Biol. 2003, 49, 183-190
https://doi.org/10.14712/fb2003049050183
Efficacy and Safety of Inhaled Recombinant Interleukin-2 in High-Risk Renal Cell Cancer Patients Compared with Systemic Interleukin-2: an Outcome Study
Crossref Cited-by Linking
- Morse Michael A.: Immunotherapy for Resected Pulmonary Metastases. Thoracic Surgery Clinics 2016, 26, 69. <https://doi.org/10.1016/j.thorsurg.2015.09.009>
- Kuzmov Andriy, Minko Tamara: Nanotechnology approaches for inhalation treatment of lung diseases. Journal of Controlled Release 2015, 219, 500. <https://doi.org/10.1016/j.jconrel.2015.07.024>
- Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K: Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Br J Cancer 2014, 110, 1427. <https://doi.org/10.1038/bjc.2014.62>
- Andrade Fernanda, Rafael Diana, Videira Mafalda, Ferreira Domingos, Sosnik Alejandro, Sarmento Bruno: Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Advanced Drug Delivery Reviews 2013, 65, 1816. <https://doi.org/10.1016/j.addr.2013.07.020>